$EVOK
Evoke Pharma Inc

2018 Q3 Form 10-Q Financial Statement

#000156459018029310 Filed on November 13, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2017 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $900.0K $980.0K
YoY Change -8.16% 18.07%
% of Gross Profit
Research & Development $630.0K $2.718M
YoY Change -76.82% 102.91%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.520M $2.718M
YoY Change -44.07% 102.91%
Operating Profit -$1.523M
YoY Change
Interest Expense $3.089K $2.822K
YoY Change 9.46% -102.35%
% of Operating Profit
Other Income/Expense, Net $3.089K -$1.541M
YoY Change -100.2% 111.14%
Pretax Income -$1.520M -$5.240M
YoY Change -70.99% 72.94%
Income Tax
% Of Pretax Income
Net Earnings -$1.519M -$5.243M
YoY Change -71.02% 73.31%
Net Earnings / Revenue
Basic Earnings Per Share -$0.09 -$0.34
Diluted Earnings Per Share -$88.73K -$0.34
COMMON SHARES
Basic Shares Outstanding 17.13M 15.35M
Diluted Shares Outstanding 17.13M 15.35M

Balance Sheet

Concept 2018 Q3 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.570M $10.41M
YoY Change -36.89% 0.29%
Cash & Equivalents $6.568M $10.41M
Short-Term Investments
Other Short-Term Assets $440.0K $330.0K
YoY Change 33.33% -25.0%
Inventory
Prepaid Expenses $439.0K
Receivables
Other Receivables
Total Short-Term Assets $7.010M $10.75M
YoY Change -34.79% -0.56%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.00K $10.00K
YoY Change 0.0%
Total Long-Term Assets $10.00K $10.00K
YoY Change 0.0%
TOTAL ASSETS
Total Short-Term Assets $7.010M $10.75M
Total Long-Term Assets $10.00K $10.00K
Total Assets $7.020M $10.76M
YoY Change -34.76% -0.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $630.0K $1.720M
YoY Change -63.37% 244.0%
Accrued Expenses $980.0K $930.0K
YoY Change 5.38% 82.35%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.610M $2.650M
YoY Change -39.25% 162.38%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $6.050M
YoY Change -100.0% 18.63%
Total Long-Term Liabilities $0.00 $6.050M
YoY Change -100.0% 18.63%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.610M $2.650M
Total Long-Term Liabilities $0.00 $6.050M
Total Liabilities $1.610M $8.700M
YoY Change -81.49% 42.39%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.408M $2.060M
YoY Change
Total Liabilities & Shareholders Equity $7.020M $10.76M
YoY Change -34.76% -0.46%

Cashflow Statement

Concept 2018 Q3 2017 Q3
OPERATING ACTIVITIES
Net Income -$1.519M -$5.243M
YoY Change -71.02% 73.31%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.150M -$2.200M
YoY Change -47.73% -9.09%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.190M 60.00K
YoY Change 1883.33% -99.31%
NET CHANGE
Cash From Operating Activities -1.150M -2.200M
Cash From Investing Activities
Cash From Financing Activities 1.190M 60.00K
Net Change In Cash 40.00K -2.140M
YoY Change -101.87% -134.24%
FREE CASH FLOW
Cash From Operating Activities -$1.150M -$2.200M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1544138
CY2017Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15351295
CY2018Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17129649
CY2017Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15351295
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Small Business
EntitySmallBusiness
true
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11551
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6567918
CY2018Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
438957
CY2017Q4 us-gaap Assets Current
AssetsCurrent
7930313
CY2017Q4 us-gaap Assets
Assets
7941864
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1048927
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1025911
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
5452
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1541316
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16327385
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14766853
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16327385
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14740977
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
7425
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-433392
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
440817
CY2018Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3089
CY2017Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2822
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.81
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3354973
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.36
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.84
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-1519468
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3089
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2018Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17129649
CY2017Q4 evok Warrant Liability
WarrantLiability
3701277
us-gaap Share Based Compensation
ShareBasedCompensation
1161266
us-gaap Share Based Compensation
ShareBasedCompensation
1404926
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5729646
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5983204
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4618297
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7389101
evok Reclassification Of Warrant Liability To Equity Due To Exercise Of Warrants
ReclassificationOfWarrantLiabilityToEquityDueToExerciseOfWarrants
1399091
evok Reclassification Of Warrant Liability To Equity Due To Amendment Of Warrants
ReclassificationOfWarrantLiabilityToEquityDueToAmendmentOfWarrants
3267885
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates. </p></div>
CY2018Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-1519468
CY2017Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-5243061
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-5805448
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
25876
CY2007Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
650000
evok Entity Incorporation Month And Year Of Incorporation
EntityIncorporationMonthAndYearOfIncorporation
2007-01
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1111349
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9007071
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-12350771
evok Amount Of Dilutive Securities Change In Fair Value Of Warrants
AmountOfDilutiveSecuritiesChangeInFairValueOfWarrants
-429702
CY2018Q3 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
47000
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
28869
CY2018Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6286425
CY2018Q2 evok Share Based Compensation Arrangement By Share Based Payment Award Expiration Month And Year
ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationMonthAndYear
2028-02
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2018Q3 us-gaap Share Based Compensation
ShareBasedCompensation
380062
CY2018Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2200000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y2M26D
CY2017Q4 us-gaap Alternative Investment Measurement Input Extensible List
AlternativeInvestmentMeasurementInputExtensibleList
evok:BlackScholesOptionPricingModelMember
CY2018Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2018Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2018Q3 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2018Q3 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0

Files In Submission

Name View Source Status
0001564590-18-029310-index-headers.html Edgar Link pending
0001564590-18-029310-index.html Edgar Link pending
0001564590-18-029310.txt Edgar Link pending
0001564590-18-029310-xbrl.zip Edgar Link pending
evok-10q_20180930.htm Edgar Link pending
evok-20180930.xml Edgar Link completed
evok-20180930.xsd Edgar Link pending
evok-20180930_cal.xml Edgar Link unprocessable
evok-20180930_def.xml Edgar Link unprocessable
evok-20180930_lab.xml Edgar Link unprocessable
evok-20180930_pre.xml Edgar Link unprocessable
evok-ex311_6.htm Edgar Link pending
evok-ex312_9.htm Edgar Link pending
evok-ex321_8.htm Edgar Link pending
evok-ex322_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending